LinkedIn
WebsiteIntroduction
Universe Pharmaceuticals Inc (NASDAQ: UPC; 유니버스 파머슈티컬스) is a biopharmaceutical manufacturer and distributor headquartered in Ji’an, Jiangxi, China, with operations extending to the U.S. East Coast. Since its initial public offering on the Nasdaq Capital Market, the company has focused on developing traditional Chinese medicine (TCM) derivatives for China’s aging population and advancing biologics in North America. As of October 8, 2025, UPC shares traded at US $7.98, reflecting a 54.35% increase, on a volume of 5,580,632.
| Ticker | Price (10/08/2025) | Change (%) | Volume | Exchange | Market Cap |
|---|---|---|---|---|---|
| UPC | US $7.98 | +54.35% | 5,580,632 | NASDAQ | US $2.9 million |
Corporate Structure and Experience
Founded in 2013, Universe Pharmaceuticals employs between 11 and 50 professionals across research and development (R&D), manufacturing, regulatory affairs, and distribution. The company's workforce includes expertise in TCM, herbal formulation, and biologics development. The Ji’an facility oversees the production and distribution of TCM derivatives, while a secondary site on the U.S. East Coast has scaled up capacity to support recently approved biologic therapies.
Biopharmaceuticals by little plant
Recent Developments and News
On March 20, 2025, Universe Pharmaceuticals announced a share consolidation plan to combine every 40 ordinary shares (par value US $0.28125) into one share (par value US $11.25), effective March 24, 2025. Following the consolidation, the company’s authorized share capital stands at US $140,625,000, divided into 11,250,000 ordinary shares and 1,250,000 preferred shares. Trading under the symbol “UPC” resumed on March 24, 2025, with a new CUSIP number (G9442G 138), and fractional shares were rounded up to whole shares.
Earlier in 2025, the U.S. Food and Drug Administration granted approval for Ekterly (sebetralstat), an oral treatment for hereditary angioedema, marking the company’s first U.S. commercial biologic launch, transitioning from injectable therapies to an oral formulation.
Financial and Strategic Analysis
Universe Pharmaceuticals reported trailing-twelve-month revenue of US $19.29 million, a gross margin of 30.4%, and a net margin of 5.65%. EBITDA for the same period was negative US $8.10 million. The reported earnings per share (EPS) of 8,030.58 reflects a low share count of approximately 563,300 shares outstanding post-consolidation and non-cash accounting adjustments. The company’s debt-to-equity ratio is 14.01%, and a beta of 1.47 indicates above-average volatility compared to the broader market.
Strategically, the share consolidation addressed minimum bid price requirements on Nasdaq, reduced the share float, and aimed to improve trading liquidity. The company’s operations in both TCM derivatives distribution throughout 30 Chinese provinces and its entry into innovative biologics in the U.S. diversify revenue streams and align with global trends regarding aging populations.
Market Position and Industry Context
In China, Universe Pharmaceuticals competes among TCM formulators and distributors by targeting geriatric wellness with derivative products and dietary supplements. Its sales network across 30 provinces provides a revenue base. In North America, the company’s entry into the hereditary angioedema treatment market with Ekterly places it within a biologics segment characterized by consolidation among specialty pharmaceutical companies. The market capitalization is approximately US $2.9 million, with a concentrated share structure, indicating limited institutional investment, although recent FDA approvals and corporate actions may attract new investors.
tl;dr
Universe Pharmaceuticals executed a 40-for-1 share consolidation on March 24, 2025, altering its capital structure and reducing share float. Its stock rose to US $7.98 on October 8, 2025, reflecting a 54.35% increase, with trading volume exceeding 5.5 million shares. The U.S. FDA approval of Ekterly for hereditary angioedema represents the company’s first commercial biologic launch in North America. These developments may enhance liquidity and diversify revenue streams in late 2025.
